Tumor Samples & in vivo Models
Tumor Samples:
- AML patient cells
- MDS patient cells
- CMML patient cells
- AML PDX
- breast samples
- lung samples
- liver samples
- pancreatic samples
- brain samples
- melanoma
Tumor Models:
- AML
- MDS
- CMML
- Pancreatic Cancer (PDAC)
- Melanoma
List of Infection & Cancer Models
MHH Research Groups
| MHH Research Group | Patient Material | Animal Models | Established Methods |
|---|---|---|---|
| AG Heuser / Thol | AML, MDS | AML, ALL, CMML | Genetic and xenograft mouse models, loss-of-function screens, genetic and phenotypic characterization of hematopoiesis; sensitive detection of mutations (NGS-MRD) |
| AG Vogel / Saborowski | HCC, CCA, precision oncology | CCA, HCC, PDAC, PDX, chronic liver injury models (FAH, MDR2, DEN, NASH/ASH) | Genetic and xenograft models, organoids, multipsectral imaging, murine hepatobiliary surgical techniques (e.g.partial hepatectomy, intrabiliary injection); Investigator- Initiated trials (hepatobiliary) |
| AG Falk | NSCLC, explanted lung tissue as comparator (Coop. Jonigk) | NSCLC | Fresh lung tissue preparation für FACS, T cell assass, single cell mRNA Seq (Seqwell, 10X CITE Seq), Microenvorinment (Luminex) |
| AG Feuerhake | Biopsy cohorts (translational biomarker studies) in collaboration with multiple clinical trials including TNBC, HCC, CAC, Sarcoma, … | EBV + DLBCL / PTLD (in collaboration with AG Stripecke), NSCLC (in collaboration with Charles River, Freiburg) | Highly multiplexed IHC (Vectra Polaris), computational & digital pathology approaches to spatially resolved TILs / TAM immunophenotyping |
| AG Göhring | Myeloid neoplasia (AML, MDS, CMML, MPN…) | Targeted RNA sequencing, DNA sequencing (exom; custom panel for haematologic neoplasia), telomere length measurement (PCR, flow cytometry, FISH), cytogenetics (chromosome analysis and FISH); all methods are accredited |
UMG Research Groups
| UMG Research Group | Patient Material | Animal Models | Established Methods |
|---|---|---|---|
| AG Chapuy |
Genomically characterized cohorts of aggressive lymphoma, total ~800 primary tumors H. pylori | Preclinical models of aggressive lymphoma | Lymphoma /Tumor (Epi)Genomics, chromatin biology, functional screens, modelling incl. PDX, analyses of cell death pathways, PD-1 mediated immune escape |
| AG Papantonis | PDAC organoids / Glioblastoma GSCs | Epigenomics (ChIP/ATAC/RNA-seq), single cell genomics, chromosome conformation (Hi-C), genome scaffolding, DNA/RNA FISH, CRISPR editing | |
| AG Ellenrieder | PDAC | Transgenic, snygeneic and PDX PDAC models; NASH/NAFLD models (Western-diet, TAA) | RNA/ChIP-Seq, DNA damage detection (e.g Comet), primary Hepatocyte isolation, Er-stress signaling, CRISPR Cas9 |
| AG Haase, INDIGHO3 | AML, MDS, MPN | Chromosome banding analysis, FISH, Multicolor FISH, NGS, cytogenetics and NGS of sorted (MACS/FACS) cell populations | |
| AG Heßmann | PDAC | Diverse transgenic PDAC models, syngeneic PDAC models, PDAC PDX models | Chromatin immunoprecipitation, diverse biochemical analysis, mouse monitoring |
Contact
Please fill out the contact form. We will get in touch with you as soon as possible.